Sun Pharma Advanced Research Company LimitedSPARCCorporate

Pharmaceuticals Latest results: Jun 2026 14 quarters of data

₹188.64

MCap ₹6,122 Cr · P/E 3.9

Sun Pharma Advanced Research Company Limited — Stock analysis & AI research Sun Pharma Advanced Research Company Limited — Seasonality — best & worst months Sun Pharma Advanced Research Company Limited — Technical indicators & charts Sun Pharma Advanced Research Company Limited — Technical setup — score, trend, support & resistance Sun Pharma Advanced Research Company Limited — Live exchange announcements

📋 High Promoter Holding Stocks 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹40 Cr

Sales · Jun 2026

+314.1% YoY

₹-34 Cr

Operating Profit · Jun 2026

+34.7% YoY

-85.2%

OPM % · Jun 2026

+84.2% YoY

₹-21 Cr

Net Profit · Jun 2026

+59.9% YoY

₹-0.64

EPS · Jun 2026

+60.0% YoY

📝 Sun Pharma Advanced Research Company Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Sun Pharma Advanced Research Company Limited reported revenue of ₹40 crore for the quarter ended June 2026 (Q1 FY27), up 314.1% from ₹10 crore in the same quarter last year, and down 97.8% sequentially over the March 2026 quarter.

The company reported a net loss of ₹21 crore, against a net loss of ₹52 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.64.

Operating profit stood at ₹-34 crore — an operating margin (OPM) of -85.2%, compared with -540.2% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Sun Pharma Advanced Research Company Limited posted revenue of ₹1,878 crore, a growth of 2512.3% over FY25, with a net profit of ₹1,553 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,909 crore with a net profit of ₹1,584 crore.

Valuation snapshot

At the current price of ₹188.64, SPARC has a market capitalisation of ₹6,122 crore and a trailing P/E of about 3.9.

Within the Pharmaceuticals industry, it is the 2nd-largest of the 82 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 65.67%, foreign institutional investors (FIIs) 3.75%, domestic institutional investors (DIIs) 0.11%, public shareholders 30.48% of Sun Pharma Advanced Research Company Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹6,122 Cr

Current Price ?

₹188.6

P/E ?

3.86below ind

Industry P/E ?

22.40

P/B ?

4.58

P/S ?

3.21

P/FCF ?

-23.37

Enterprise Value ?

₹6,681 Cr

EV/EBITDA ?

4.13

PEG ?

0.04

Earnings Yield ?

24.0%

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹1,909 Cr

OPM ?

84.7%

Profit after tax (TTM) ?

₹1,584 Cr

EPS (TTM) ?

₹48.82

ROCE ?

164.0%

ROE ?

118.4%

ROA ?

73.0%

Growth

Sales — latest qtr ?

₹40 Cr

PAT — latest qtr ?

₹-21 Cr

YoY qtr sales growth ?

314.1%

YoY qtr profit growth ?

59.9%

Sales growth (3y) ?

99%

Sales growth (5y) ?

N/A

Profit growth (3y) ?

108%

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹559 Cr

Debt to Equity ?

0.42

Interest Coverage ?

45.7

Current Ratio ?

N/A

Ownership

Promoter holding ?

65.67%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

-19.8%

Return 6 months ?

27.5%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	48	24	21	14	17	17	13	15	27	10	8	8	1,853	40	+314.1%	-97.8%
Operating Profit	-90	-102	-91	-103	-106	-93	-103	-74	-53	-52	-66	-57	1,773	-34	+34.7%	-101.9%
Other Income	11	10	8	6	4	2	0	0	0	9	0	-12	2	24	+158.9%	+1083.0%
Interest	0	0	0	0	1	1	1	3	5	6	8	9	12	8	+31.3%	-32.2%
Depreciation	3	3	3	3	3	3	3	3	3	3	3	3	2	2	-17.9%	+10.0%
Profit Before Tax	-82	-95	-86	-100	-105	-96	-107	-79	-61	-52	-76	-80	1,761	-21	+60.1%	-101.2%
Net Profit	-82	-95	-86	-100	-106	-96	-107	-80	-60	-52	-76	-80	1,761	-21	+59.9%	-101.2%
EPS	-2.53	-2.94	-2.66	-3.07	-3.26	-2.96	-3.31	-2.45	-1.84	-1.60	-2.34	-2.48	54.27	-0.64	+60.0%	-101.2%
OPM %	-187.5%	-425.0%	-431.9%	-735.7%	-623.5%	-555.4%	-792.3%	-494.2%	-195.6%	-540.2%	-836.1%	-712.5%	95.7%	-85.2%	+84.2%	-189.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹72 Cr	₹1,878 Cr	₹1,909 Cr	+2512.3%
Operating Profit	₹-323 Cr	₹1,598 Cr	₹1,616 Cr	+594.4%
OPM %	-449.49%	85.08%	84.68%	+118.9%
NPM %	-475.84%	82.69%	83.00%	+117.4%
Other Income	₹2 Cr	₹-1 Cr	₹14 Cr	-148.6%
Depreciation	₹12 Cr	₹10 Cr	₹10 Cr	-16.3%
Interest	₹9 Cr	₹35 Cr	₹37 Cr	+290.0%
EBIT	₹-335 Cr	₹1,588 Cr	₹1,607 Cr	+573.4%
PBT	₹-343 Cr	₹1,553 Cr	₹1,585 Cr	+553.4%
Tax	₹0 Cr	₹0 Cr	₹0 Cr	-74.5%
Net Profit	₹-342 Cr	₹1,553 Cr	₹1,584 Cr	+553.9%
EPS	₹-10.56	₹47.85	₹48.81	+553.1%
Material Cost	₹15 Cr	₹11 Cr	₹14 Cr	-24.2%
Employee Cost	₹115 Cr	₹61 Cr	₹59 Cr	-47.2%
Extraordinary Items	—	—	—	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	32	32	32	32	+0.0%
Reserves	480	93	-249	1,306	+624.5%
Borrowings	16	61	269	559	+107.8%
Other Liabilities	302	328	284	273	-3.9%
Total Liabilities	830	515	336	2,171	+546.1%
Fixed Assets	106	108	99	157	+58.6%
CWIP	27	44	54	0	-100.0%
Investments	291	2	0	0	—
Other Assets	406	362	183	2,014	+1000.5%
Total Assets	830	515	336	2,171	+546.1%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	-69	-429	-360	-239	+33.6%
Cash from Investing Activity	-548	392	158	-24	-115.2%
Cash from Financing Activity	617	42	199	261	+31.2%
Net Cash Flow	-1	5	-3	-1	+66.7%
Free Cash Flow	-84	-455	-370	-262	+29.2%
CFO/OP	35%	106%	114%	-17%	-114.9%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	50	75	82	2	-97.6%
Cash Conversion Cycle	50	75	82	2	-97.6%
Working Capital Days	-193	-738	-1,780	215	+112.1%
ROCE %	—	-108%	-279%	164%	+158.8%

👥 Shareholding (latest 6 periods)

Metric	Sep 2025	Dec 2025	Mar 2026	May 2026	Jun 2026	Sep 2026	% Chg
Promoters	65.67%	65.67%	65.67%	65.68%	65.67%	65.67%	+0.0%
FIIs	1.76%	2.04%	2.04%	2.48%	3.90%	3.75%	-3.8%
DIIs	1.05%	0.78%	0.88%	0.10%	0.09%	0.11%	+22.2%
Public	31.52%	31.51%	31.41%	31.77%	30.33%	30.48%	+0.5%
No. of Shareholders	1,36,997	1,44,810	1,40,625	1,37,538	1,41,957	1,41,992	+0.0%

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 82 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SUDEEPPHRM Sudeep Pharma	₹1,033.30	11,671	63.3	675	184	34.6%	27.3%	—	—	26.6%	30.9%
2	SPARC Sun Pharma	₹185.08	6,006	3.8	1,909	1,584	84.7%	83.0%	2512.3%	553.9%	314.1%	59.9%
3	GUJTHEM Gujarat Themis	₹412.60	5,370	92.3	173	48	47.3%	27.8%	8.6%	-6.1%	21.6%	23.0%
4	539997 Kwality Pharmaceuticals	₹2,652.10	3,525	34.0	553	81	24.4%	14.6%	35.7%	71.8%	46.3%	113.5%
5	524632 Shukra Pharmaceuticals	₹80.95	2,403	99.9	75	36	65.0%	48.2%	74.0%	130.1%	336.4%	1359.2%
6	FERMENTA Fermenta Biotech	₹475.00	1,362	21.4	501	64	18.9%	12.7%	—	—	-17.9%	-30.6%
7	506414 Fermenta Biotech	₹552.60	1,313	27.2	511	59	17.6%	11.5%	11.9%	-6.6%	-10.4%	-56.7%
8	AHCL Anlon Healthcare	₹20.20	1,074	—	—	—	—	—	—	—	163.0%	133.3%
9	541096 Bharat Parenterals	₹1,525.00	1,062	—	323	-30	3.3%	-9.3%	1.5%	37.5%	-19.2%	-309.6%
10	540737 Shree Ganesh	₹796.30	855	66.2	99	15	31.4%	15.6%	0.7%	-23.0%	-41.8%	-67.5%
11	AMANTA Amanta Healthcare	₹197.75	768	52.5	291	15	20.4%	5.0%	—	—	5.4%	-5.6%
12	539730 Fredun Pharmaceuticals	₹827.85	611	10.3	747	44	14.7%	5.9%	40.1%	90.0%	90.2%	88.1%
13	500422 Transchem Ltd-$	₹38.00	474	10.8	—	4	—	—	-100.0%	-17.8%	-100.0%	186.3%
14	HALEOSLABS Haleos Labs	₹1,525.00	461	21.0	324	15	12.6%	4.7%	-3.2%	-4.9%	-11.6%	-58.0%
15	524731 Jenburkt Pharmaceuticals	₹865.75	404	11.6	170	33	23.6%	19.4%	11.8%	6.1%	-1.4%	-26.4%
16	543616 Trident Lifeline	₹279.85	364	14.0	134	24	24.6%	17.9%	—	—	42.6%	44.2%
17	512600 Astal Laboratories	₹75.00	308	32.3	170	10	8.8%	5.7%	142.9%	-9.0%	56.0%	77.4%
18	524828 BDH Industries	₹336.80	300	16.6	100	12	15.3%	11.7%	44.3%	16.6%	20.2%	48.8%
19	500009 Ambalal Sarabhai	₹38.73	297	21.9	206	14	7.1%	6.6%	3.1%	261.1%	8.0%	-51.6%
20	532039 Zenotech Laboratories	₹64.90	263	—	45	-3	17.0%	-5.6%	1.3%	-119.2%	10.1%	-146.0%
21	531739 Gennex Laboratories	₹13.87	255	19.0	183	21	14.4%	11.3%	24.9%	15.5%	16.6%	-6.9%
22	524790 Everest Organics	₹159.20	252	29.4	191	5	10.3%	2.8%	23.0%	527.7%	-10.0%	-21.1%
23	530163 Kerala Ayurveda	₹310.20	225	—	125	-26	-14.9%	-20.8%	9.0%	-16.8%	-21.3%	-477.8%
24	531569 Sanjivani Paranteral	₹199.95	214	32.7	66	7	15.3%	11.3%	-7.6%	-14.4%	8.8%	32.7%
25	524636 Oxygenta Pharmaceutical	₹32.25	195	—	135	-14	-5.9%	-10.1%	3.3%	-70.8%	144.5%	65.6%

❓ Frequently asked questions

What was Sun Pharma Advanced Research Company Limited's revenue in Q1 FY27?

What was Sun Pharma Advanced Research Company Limited's net profit in Q1 FY27?